Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares stood at 1.21 million during the last session, with the company’s beta value hitting 0.36. At the close of trading, the stock’s price was $0.40, to imply an increase of 13.96% or $0.05 in intraday trading. The BCLI share’s 52-week high remains $2.06, putting it -415.0% down since that peak but still an impressive 67.5% since price per share fell to its 52-week low of $0.13. The company has a valuation of $31.83M, with an average of 660.23K shares over the past 3 months.
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) trade information
After registering a 13.96% upside in the last session, Brainstorm Cell Therapeutics, Inc. (BCLI) has traded red over the past five days. The stock hit a weekly high of 0.4158, jumping 13.96% in its intraday price action. The 5-day price performance for the stock is 16.82%, and -7.62% over 30 days. With these gigs, the year-to-date price performance is 46.52%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Brainstorm Cell Therapeutics, Inc. (BCLI) estimates and forecasts
Looking at statistics comparing Brainstorm Cell Therapeutics, Inc. share performance against respective industry, we note that the company has outperformed competitors. Brainstorm Cell Therapeutics, Inc. (BCLI) shares are 21.51% up over the last 6 months, with its year-to-date growth rate higher than industry average at 45.10% against 15.40%.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc. has its next earnings report out in August. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Brainstorm Cell Therapeutics, Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.